Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine.

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine.
复制标题

DOI:
10.1038/s41541-023-00619-9
复制
发表时间:
2023-02-18
期刊:
影响因子:
9.2
通讯作者:
--
中科院分区:
医学1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

一种阻断寄生虫从人到蚊子传播的疟疾疫苗将是破坏寄生虫生命周期和降低人类疾病发病率的有力方法。Pfs 48/45是一种正在开发的有前途的抗原,可作为针对最致命的恶性疟原虫的传播阻断疫苗(TBV)。Pfs 48/45(D3)的第三个域是一个既定的TBV候选者,但生产挑战阻碍了开发。例如,迄今为止,当在真核系统中产生时,需要非天然N-聚糖来稳定结构域。在这里,我们实施了SPEEDesign计算设计和体外筛选管道,保留了Pfs 48/45中有效的传输阻断表位,同时创建了具有改进特性的稳定的非糖基化Pfs 48/45 D3抗原用于疫苗生产。这种抗原可以通过基因融合到一种自组装的单组分纳米颗粒上,从而产生一种疫苗,在低剂量下在啮齿动物中产生有效的减少传播的活性。增强的Pfs 48/45抗原使许多新的和强大的方法来TBV的发展,这种抗原设计方法可以广泛应用于其他疫苗抗原和治疗剂的设计,而不干扰聚糖。
A malaria vaccine that blocks parasite transmission from human to mosquito would be a powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in humans. Pfs48/45 is a promising antigen in development as a transmission blocking vaccine (TBV) against the deadliest malaria parasite Plasmodium falciparum. The third domain of Pfs48/45 (D3) is an established TBV candidate, but production challenges have hampered development. For example, to date, a non-native N-glycan is required to stabilize the domain when produced in eukaryotic systems. Here, we implement a SPEEDesign computational design and in vitro screening pipeline that retains the potent transmission blocking epitope in Pfs48/45 while creating a stabilized non-glycosylated Pfs48/45 D3 antigen with improved characteristics for vaccine manufacture. This antigen can be genetically fused to a self-assembling single-component nanoparticle, resulting in a vaccine that elicits potent transmission-reducing activity in rodents at low doses. The enhanced Pfs48/45 antigen enables many new and powerful approaches to TBV development, and this antigen design method can be broadly applied towards the design of other vaccine antigens and therapeutics without interfering glycans.
DOI: 10.1371/journal.ppat.1003390
发表时间: 2013
期刊: PLoS pathogens
影响因子: 6.7
作者:
Chen E;Paing MM;Salinas N;Sim BK;Tolia NH
通讯作者: Tolia NH
DOI: 10.1016/j.ijpara.2016.10.002
发表时间: 2017-06
影响因子: 4
作者:
Arredondo SA;Kappe SHI
通讯作者: Kappe SHI
DOI: 10.1038/s41541-021-00330-7
发表时间: 2021-05-13
期刊: NPJ vaccines
影响因子: 9.2
作者:
Nguyen B;Tolia NH
通讯作者: Tolia NH
DOI: 10.1371/journal.pone.0006352
发表时间: 2009-07-22
期刊: PloS one
影响因子: 3.7
作者:
Chowdhury DR;Angov E;Kariuki T;Kumar N
通讯作者: Kumar N
DOI: 10.7554/elife.21347.001
发表时间: 2017-02-14
期刊: ELIFE
影响因子: 7.7
作者:
Chen, Lin;Xu, Yibin;Cowman, Alan F.
通讯作者: Cowman, Alan F.